Miriam Bibel, Autoimmunity, Transplantation and Inflammation

Novartis has been in the front ranks of a revolution in the treatment of malaria, launching the first fixed-dose artemisinin-based combination therapy (ACT) in 1999 and the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV) in 2009.

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.

Download (PDF 254.65 KB)